These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19089671)

  • 1. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
    LaRocca RV; Hicks MD; Mull L; Foreman B
    J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
    Qun W; Tao Y
    Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
    Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
    J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
    Bengala C; Bertolini F; Malavasi N; Boni C; Aitini E; Dealis C; Zironi S; Depenni R; Fontana A; Del Giovane C; Luppi G; Conte P
    Br J Cancer; 2010 Jan; 102(1):68-72. PubMed ID: 19935794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
    Luo X; Jia W; Huang Z; Li X; Xing B; Jiang X; Li J; Si A; Yang T; Gao C; Lau WY; Shen F
    Oncotarget; 2017 Mar; 8(10):17246-17257. PubMed ID: 27783997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
    Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
    El-Khoueiry AB; Rankin C; Siegel AB; Iqbal S; Gong IY; Micetich KC; Kayaleh OR; Lenz HJ; Blanke CD
    Br J Cancer; 2014 Feb; 110(4):882-7. PubMed ID: 24423918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Strumberg D
    Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
    Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
    Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
    Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
    Pinter M; Sieghart W; Reisegger M; Wrba F; Peck-Radosavljevic M
    Wien Klin Wochenschr; 2011 Jan; 123(1-2):61-4. PubMed ID: 21240686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ; Kolesar JM
    Am J Health Syst Pharm; 2008 Jan; 65(2):123-31. PubMed ID: 18192256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy for hepatocellular carcinoma and cholangiocarcinoma.
    Chung V
    Surg Oncol Clin N Am; 2015 Jan; 24(1):187-98. PubMed ID: 25444475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
    Bracarda S; Caserta C; Sordini L; Rossi M; Hamzay A; Crinò L
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi22-5. PubMed ID: 17591826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
    Wilhelm S; Carter C; Lynch M; Lowinger T; Dumas J; Smith RA; Schwartz B; Simantov R; Kelley S
    Nat Rev Drug Discov; 2006 Oct; 5(10):835-44. PubMed ID: 17016424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
    Wilhelm SM; Adnane L; Newell P; Villanueva A; Llovet JM; Lynch M
    Mol Cancer Ther; 2008 Oct; 7(10):3129-40. PubMed ID: 18852116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
    Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
    Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.